<DOC>
	<DOCNO>NCT00630994</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , decitabine , work different way stop growth cancer cell , either kill cell stop dividing . PURPOSE : This phase II trial study side effect well low-dose decitabine work treat patient symptomatic myelofibrosis .</brief_summary>
	<brief_title>Low-Dose Decitabine Treating Patients With Symptomatic Myelofibrosis</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy safety low-dose decitabine patient symptomatic primary myelofibrosis ( PMF ) post essential thrombocythemic ( ET ) polycythemic vera ( PV ) myelofibrosis . - Analyze ability drug decrease pathologic angiogenesis stromal reactive feature intrinsic PMF post ET/PV myelofibrosis . OUTLINE : Patients receive low-dose decitabine IV 1 hour day 1-5 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Patients achieve partial remission , complete remission , clinical improvement may receive 12 course decitabine absence disease progression unacceptable toxicity . After completion study therapy , patient follow periodically 3 year .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histological confirmation primary myelofibrosis post essential thrombocythemic polycythemic vera myelofibrosis Reticulin fibrosis ≥ grade 1 Evaluable symptomatic disease worthy treatment , characterize ≥ 1 following : Anemia , define hemoglobin &lt; 11 g/dL erythrocyte transfusion dependence Palpable symptomatic splenomegaly ( palpable symptomatic hepatomegaly acceptable previously splenectomized ) Severe , diseaserelated constitutional symptom , include ≥ 1 following : Severe night sweat Fevers Weight loss Bone pain Absence ( 9 ; 22 ) fluorescent situ hybridization ( FISH ) standard cytogenetics OR prior demonstration lack translocation PATIENT CHARACTERISTICS : Eastern Cooperative Oncology Group ( ECOG ) performance status 03 Absolute neutrophil count ( ANC ) ≥ 1,000/mm³ Platelet count ≥ 50,000/mm³ Creatinine ≤ 2.0 mg/dL Direct total bilirubin ≤ 2.0 mg/dL Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 3 time upper limit normal ( ULN ) ( ≤ 5 time ULN elevation attribute hepatic extramedullary hematopoiesis ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Not incarcerated municipality , county , state , federal prison No serious medical condition psychiatric illness would preclude sign informed consent No condition , opinion treat physician , place patient unacceptable risk study participation confound ability interpret study data Able adhere study visit schedule study requirement PRIOR CONCURRENT THERAPY : No concurrent chemotherapy ( e.g. , hydroxyurea , thalidomide , interferon alpha , anagrelide , myelosuppressive agent ) experimental therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>primary myelofibrosis</keyword>
	<keyword>secondary myelofibrosis</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>polycythemia vera</keyword>
</DOC>